Cancer patients can’t afford care
Lost in the debate on “Trumpcare” versus “Obamacare” is the proper consideration of the factors driving increasing health care costs. In cancer, the pharmaceutical industry plays a major role setting drug prices that exceed reasonable returns on research and development. The economics of treatment were again apparent during the plenary session of the American Society of Clinical Oncology Annual Meeting in June, aka the cancer community’s Super Bowl. Two years …